Cutaneous leishmaniasis. Cutaneous leishmaniasis
Conditions
Interventions
Intervention 1: Sequentially numbered identical-looking vials of vaccine or phosphate buffer saline (PBS) were produced. A random list of codes for vials were prepared. Volunteers will be inoculated
Treatment - Drugs
Sequentially numbered identical-looking vials of vaccine or phosphate buffer saline (PBS) were produced. A random list of codes for vials were prepared. Volunteers will be inoculated intradermally PB
Sequentially numbered identical-looking vials of vaccine or placebo were produced, A random list of codes for vials were prepared. Volunteers will be vaccinated promastigotes suspension (0•1 mL) in t
Sponsors
Kerman University of Medical Sceinces
Eligibility
Sex/Gender
All
Age
3 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion and exclusion criteria: Inclusion criteria: Otherwise healthy; age: 3-75 years; sign the consent form willingly to participate in this study. Exclusion criteria: History of leishmaniasis or any scar resembling cutaneous leishmaniasis; pregnant; acute or chronic disease; history of allergic; diabetic; history of vaccination in the previous month;history of autoimmunity, immune deficiency or immune suppression therapy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunity to cutaneous lesions. Timepoint: After vaccination. Method of measurement: Observation, examine by routine methods with. | — |
Secondary
| Measure | Time frame |
|---|---|
| Redness, induration and ulcer at the site of injection. Timepoint: After vaccination. Method of measurement: Measuring the size of induration.;Pain and itching site of injection, lymphadenopathy. Timepoint: After vaccination. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Daneshvar
Kerman University ofMedical Sceinces
Outcome results
None listed